Recommended Topic Related To:


"On December 16, 2014, the U. S. Food and Drug Administration approved lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroe"...


Side Effects


Side effects of photopheresis (UVADEX™ used with the THERAKOS™ Photopheresis System) were primarily related to hypotension secondary to changes in extracorporeal volume ( > 1%). In study CTCL 3 (UVADEX™), six serious cardiovascular adverse experiences were reported in five patients (5/51, 10%). Five of these six events were not related to photopheresis and did not interfere with the scheduled photopheresis treatments. One patient (1/51, 2%) with ischemic heart disease had an arrhythmia after the first day of photopheresis that was resolved the next day. Six infections were also reported in five patients. Two of the six events were Hickman catheter infections in one patient, which did not interrupt the scheduled photopheresis. The other four infections were not related to photopheresis and did not interfere with scheduled treatments.


An analysis of postmarketing data shows the following events occurred with an incidence of < 0.01%: rash, allergic reaction, pyrexia, nausea, dysgeusia.

Read the Uvadex (methoxsalen) Side Effects Center for a complete guide to possible side effects


See WARNINGS Section.

Read the Uvadex Drug Interactions Center for a complete guide to possible interactions

Last reviewed on RxList: 11/27/2013
This monograph has been modified to include the generic and brand name in many instances.

Side Effects

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get the latest treatment options.